Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELIOS: Proactive TDM vs Routine Care With Novel Biologics in Psoriasis
NCT06398106Phase 4Recruiting
- Sponsor
- Ghent University Hospital
- Start
- Dec 2024
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of secukinumab, ixekizumab, guselkumab in Psoriasis vulgaris (PV), sponsored by Ghent University Hospital. Started Dec 2024; status: recruiting.
02
Drugs
secukinumabixekizumabguselkumab
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT06398106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06398106.